Related Experiment Video
Updated: Apr 22, 2026
09:46
Megakaryocyte Differentiation and Platelet Formation from Human Cord Blood-derived CD34+ Cells
Published on: December 27, 2017
19.4K
Management of thrombocythemia
1Department of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, 85259, USA.
F1000Research
|October 18, 2014
Summary
Essential thrombocythemia, a myeloproliferative neoplasm, requires accurate diagnosis and risk stratification. Treatment focuses on reducing thrombotic risk with aspirin and cytoreductive therapy, with new agents under investigation.
Area of Science:
- Hematology
- Oncology
Background:
- Essential thrombocythemia is a clonal myeloproliferative neoplasm characterized by elevated platelet counts.
- It carries risks of microvascular/macrovascular complications and transformation to myelofibrosis or acute myeloid leukemia.
Purpose of the Study:
- To outline the diagnostic, risk stratification, and therapeutic approaches for essential thrombocythemia.
- To discuss current and emerging treatment options.
Main Methods:
- Systematic initial analysis for accurate diagnosis, differentiating from reactive causes.
- Risk stratification and symptom assessment to guide therapy.
- Review of current first-line cytoreductive therapies (hydroxyurea, pegylated interferon) and agents for refractory cases (anagrelide).
Main Results:
- Accurate diagnosis is crucial as many causes are benign.
- High-risk patients (e.g., advanced age, prior thrombosis) may require treatment.
- Current therapy includes aspirin and cytoreductive agents; a trial compares hydroxyurea and pegylated interferon.
Conclusions:
- Risk stratification and symptom assessment are vital for managing essential thrombocythemia.
- Current treatments aim to reduce thrombotic risk.
- Emerging therapies like JAK2 and telomerase inhibitors show promise for future treatment.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
480
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
480
01:30Venous Thrombosis IV: Nursing Management
405
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
405
01:14Myocarditis III: Medical Management
340
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
340
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
681
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
681
01:18Chronic Kidney Disease IV: Nursing Management
671
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
671
01:27Peripheral Artery Disease III: Interprofessional Care
641
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
641